A novel approach for delivery of enzyme drugs: Preliminary demonstration of feasibility and utility in vitro

Jun F. Liang, Yong T. Li, Victor C. Yang

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

A novel heparin/protamine-based approach for delivery of enzyme drugs without associated toxic effects has been proposed. This approach would allow an enzyme drug to be administered in an inactive (i.e. pro-drug) form and then released at the target site in an active form using protamine as the triggering agent. The pro-drug and the triggered release features of this approach would permit the enzyme drug to act specifically and only on its target substrates while sparing normal substrates, thereby alleviating unwanted toxic effects. The in vitro feasibility of the approach has been successfully demonstrated using trypsin as the model protease drug. In addition, the utility of the approach has also been demonstrated by applying the system in delivering streptokinase, one of the most widely used clinical drugs in thrombolytic therapy. This approach may open up the possibility of developing a wide range of new catalytic drugs that are initially thought to be impossible for therapeutic use due to their potent toxic effects. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalInternational Journal of Pharmaceutics
Volume202
Issue number1-2
DOIs
StatePublished - 20 Jul 2000

Keywords

  • Enzyme drugs
  • Heparin
  • Pro-drug feature
  • Protamine
  • Streptokinase
  • Triggered release feature

Fingerprint

Dive into the research topics of 'A novel approach for delivery of enzyme drugs: Preliminary demonstration of feasibility and utility in vitro'. Together they form a unique fingerprint.

Cite this